“We have made significant progress to date in 2023, achieving several important clinical and corporate milestones, as we continue to build a leading genetic medicine company,” said R. Nolan Townsend, Chief Executive Officer of Lexeo. “With the successful completion of our IPO, we are well positioned to execute on our near-term corporate objectives. Importantly, as we head into 2024, we expect to provide additional clinical data readouts from our lead cardiovascular and APOE4-associated Alzheimer’s disease programs, continuing our momentum into the new year.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on LXEO:
- J.P. Morgan Recommends These 2 ‘Strong Buy’ Stocks With Over 60% Upside Potential
- Lexeo Therapeutics initiated with a Buy at Chardan
- Lexeo Therapeutics initiated with an Outperform at Leerink
- Lexeo Therapeutics initiated with an Outperform at RBC Capital
- Lexeo Therapeutics initiated with a Buy at Stifel